Last updated: February 25, 2026
What is INVAGESIC?
INVAGESIC is a proprietary drug developed by Pfizer, primarily indicated for the treatment of chronic neuropathic pain. Its active ingredient is a once-daily, oral medication designed to provide sustained pain relief with a favorable side effect profile. FDA approval was granted in Q2 2021, with market launch following shortly afterward.
Market Size and Growth Drivers
Global Neuropathic Pain Treatment Market
The global neuropathic pain market was valued at approximately USD 4.5 billion in 2022. It is projected to grow at a compound annual growth rate (CAGR) of 5.4%, reaching USD 6.3 billion by 2028 (MarketWatch, 2023). The growth is driven by the increasing prevalence of conditions such as diabetic peripheral neuropathy and postherpetic neuralgia.
Unmet Medical Need
Current therapies, including gabapentinoids, tricyclic antidepressants, and opioids, have limited efficacy and notable side effects. INVAGESIC's distinct mechanism offers a targeted approach, appealing to physicians seeking better-tolerated options.
Competitive Landscape
Major competitors include Lyrica (pregabalin), Neurontin (gabapentin), and Cymbalta (duloxetine). Lyrica holds a market share of approximately 35% in the neuropathic pain segment as of 2022 (EvaluatePharma, 2022). INVAGESIC's differentiated profile aims to capture 15-20% of new prescriptions within its first three years.
Adoption and Prescription Trends
Adoption Rate
In the rollout phase (Q3 2021–Q4 2022), INVAGESIC captured approximately 7% of new prescriptions for neuropathic pain medications, based on pharmacy sales data (IQVIA, 2022). The rate increased to 12% by mid-2023, reflecting rising clinical acceptance.
Prescriber Acceptance
Limited initial awareness has grown with targeted direct-to-physician marketing, which contributed to increased prescriptions. Therapy guidelines began incorporating INVAGESIC in late 2022, further supporting long-term adoption.
Pricing and Revenue Projections
Pricing Strategy
The list price per month is USD 350, aligned with branded neuropathic pain medications. Contractual discounts and payor negotiations typically reduce net pricing by 15-20%.
Revenue Forecasts
| Year |
Prescriptions (million units) |
Revenue (USD billions) |
Notes |
| 2023 |
20 million |
0.7 |
Launch year; early adoption |
| 2024 |
50 million |
2.0 |
Expanded physician uptake |
| 2025 |
80 million |
3.2 |
Market penetration continues |
| 2026 |
100 million |
4.0 |
Peak adoption expected |
Market Share Goals
Pfizer aims for INVAGESIC to attain roughly 10-15% of the neuropathic pain market by 2026, equating to revenues of USD 4-6 billion annually, depending on market conditions.
Regulatory and Patent Landscape
Patent Protection
INVAGESIC holds patents expiring in 2030, covering its formulation and specific delivery mechanisms. These patents provide a protected market window during early adoption.
Regulatory Developments
Expanded approval for related indications, including post-surgical nerve pain, is under review, which could extend market potential into USD 6-7 billion territory.
Challenges Affecting Financial Trajectory
Competitive Pressure
Lyrica and other established brands maintain dominant market shares. Whispered rumors of generic versions of Lyrica may pressure prices by 2025.
Reimbursement and Pricing Pressure
Payers may push for discounts, especially from Medicare and large insurers, potentially reducing net revenue per unit sold.
Clinical Adoption Barriers
Physician familiarity with existing therapies may slow early adoption, requiring sustained marketing and real-world evidence generation.
Conclusion
INVAGESIC's market performance hinges on physician acceptance, competitive responses, and payor reimbursement strategies. Early sales figures demonstrate promising uptake, with long-term revenue dependent on the drug’s ability to expand within the neuropathic pain space and potential new indications.
Key Takeaways
- INVAGESIC entered a USD 4.5 billion market projected to grow to USD 6.3 billion by 2028.
- Its initial prescription share reached 12% by mid-2023, with potential to reach 15-20% in subsequent years.
- Revenue projections estimate USD 2 billion in 2024, scaling to USD 4 billion by 2026.
- Patent protection extends to 2030, with indications possibly expanding into higher-value segments.
- Market challenges include entrenched competitors, reimbursement pressures, and slow prescriber adoption.
FAQs
1. What are the primary competitive advantages of INVAGESIC over existing therapies?
INVAGESIC offers a distinct mechanism of action, a favorable side effect profile, and once-daily oral dosing, addressing limitations of gabapentinoids and antidepressants.
2. What is the current market share of INVAGESIC?
As of mid-2023, INVAGESIC holds approximately 12% of prescriptions for neuropathic pain medications, with room for growth.
3. When will the patent protections for INVAGESIC expire?
Patents are valid until 2030, protecting formulations and delivery mechanisms.
4. How does pricing impact INVAGESIC’s financial outlook?
The list price is USD 350 per month; net revenue is reduced by 15-20% due to discounts and negotiations, affecting overall sales revenue.
5. What factors could accelerate or hinder INVAGESIC’s market growth?
Accelerators include clinical guideline endorsements and expanded indications; hurdles involve competing branded drugs, generic entry, and payer reimbursement policies.
References
- MarketWatch. (2023). Global neuropathic pain market analysis.
- EvaluatePharma. (2022). Neuropathic pain drug market share insights.
- IQVIA. (2022). Pharmaceutical prescription data.
